Neoadjuvant Durvalumab Shows Benefit in Triple-Negative Breast Cancer

January 3, 2020

David Rimm, MD, PhD, discusses the key takeaways from the results of a phase I/II trial presented in a poster at the 2019 San Antonio Breast Cancer Symposium, which evaluated neoadjuvant checkpoint inhibition in a small subset of patients with triple-negative breast cancer.<br /> &nbsp;

David Rimm, MD, PhD, a pathologist at Yale University School of Medicine and professor in the Department of Pathology and Department of Medical Oncology, discusses the key takeaways from the results of a phase I/II trial presented in a poster at the 2019 San Antonio Breast Cancer Symposium, which evaluated neoadjuvant checkpoint inhibition in a small subset of patients with triple-negative breast cancer (TNBC).

A durvalumab (Imfinzi)-based regimen improved outcomes in patients with TNBC compared with chemotherapy alone. These findings were consistent with those of KEYNOTE-522, which evaluated the checkpoint inhibitor pembrolizumab (Keytruda) in a larger population. However, this small trial compared the antibody to PD-L1 ligand as opposed to in comparison with the PD-1 receptor in KEYNOTE-522, says Rimm.